Navigation Links
As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards

SYDNEY, Jan. 4, 2012 /PRNewswire/ -- The Company today announced that it has modified the provisions of its American Depository Receipt ("ADR") program.  The previous conversion ratio of 5 Novogen Limited ordinary shares for each ADR share will now be 25 Novogen Limited ordinary shares for each ADR share.  The change will be effective from 3 January, 2012.  The change in the ADR ratio will have no effect on the number of outstanding common shares the company has on issue or the listing of its common shares on the ASX.

In making the announcement, William D Rueckert, Chairman stated: "The ratio change and resulting increase in the market price for our ADR shares, as listed on NASDAQ, will bring our ADR shares back into compliance with NASDAQ's $1.00 minimum bid price requirement. We believe that continued listing on both the ASX and NASDAQ provides important liquidity on two major exchanges for our shareholders and for the Company."

In a separate transaction, the Company also announced today that it has made an additional investment in its majority owned drug development subsidiary, Marshall Edwards with the purchase 1,941,747 common shares for a total of $2,000,000. The proceeds will support the continued development of Marshall Edward's drug development programs.

About Novogen Limited

Novogen Limited (ASX: NRT, Nasdaq: NVGN, Nasdaq: NVGND) is an Australian biotechnology company based in Sydney, Australia.  Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc.  More information on the Novogen group of companies can be found at

SOURCE Novogen Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. New Report on 633 Biotechnology Medicines Under Development Released in Michigan
2. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
3. Beckman Coulter Announces First Quarter 2009 Earnings to be Released on Tuesday, April 28, 2009, After Market Closes
4. New cow genome sequence released
5. GeneCards(R) Version 3.0 Beta Released
6. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
7. Prescription-Free Digital Hearing Aid Just Released
8. Jatropha Couple Oil Crop Cultivation Technology Commercially Released
9. Sevocity EHR 08 Released With ARRA (Stimulus) Commitment
10. The 2010 Bio-IT World Best Practices Call for Entries has been Released -- Highlight your Company's Excellence in Innovation
11. Novel Imaging Software Released by Celsense Inc.
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global ... Practice (GMP) 10000 in the Santiago Marriott. The Global Stem Cells Group GMP ... a world-class team of qualified medical researchers and practitioners, experienced in administering stem ...
(Date:11/30/2015)... interventional radiology technique shows promise for helping morbidly obese patients ... being presented today at the annual meeting of the Radiological ... --> --> Gastric artery ... a way to stop bleeding in emergency situations, but the ... obesity is new. Mubin Syed , M.D., interventional ...
(Date:11/30/2015)... , December 1, 2015 Partnership includes ... for the u niversity , ... support treatment s cale - up ... (ARVs)   Africa , where licensees based anywhere in ... based on SDN technology. --> Africa , where licensees based ...
(Date:11/30/2015)... Mass. , Nov. 30, 2015 ... HART ), a biotechnology company developing bioengineered organ ... received written notification from The NASDAQ Stock Market ... bid price requirements. The letter noted that as ... HART,s common stock having exceeded $1.00 per share ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
Breaking Biology News(10 mins):